Skip to main content
NBIX logo

NBIX · Neurocrine Biosciences Inc · Share Buybacks

Track NBIX — free
$148.45 +2.45 (+1.68%) Q2 2026 earnings call transcript
Market Cap
$14.84B
Shares
101.65M
Volume · Oct 28 1.09M Avg daily vol (3M) 1.31M

Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.

Program Authorized
$500,000,000
as of 2025-02-28
Remaining Authorization
$266,300,000
as of 2026-06-30
Program Utilization
46.7% $233,700,000 used of $500,000,000

Cash spent on buybacks by quarter

Cash deployed each quarter, with the average price paid where the company reported it. Δ marks quarters derived from the company's cumulative year-to-date disclosures.

Repurchase History

Fiscal Year Ended Cash Spent
2026-06-30 YTD $66,000,000
2025-12-31 $167,700,000
2024-12-31 $300,000,000
Key facts CIK 914475 CUSIP 64125C109 13F (30d) 195 filings 184 filers Visit website Investor relations